Massmutual Corporate Investors (MCI) 17.63 $MCI Babson

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Massmutual Corporate Investors (MCI) 17.63 $MCI

Babson Capital Corporate Investors Conducts 2016 Annual Shareholder Meeting
PR Newswire - Fri Apr 22, 1:45PM CDT
The Board of Trustees of Babson Capital Corporate Investors (the "Trust" met on April 22, 2016. The Trust also conducted its 2016 Annual Meeting of Shareholders.
MCI: 17.63 (-0.26)

Babson Capital Corporate Investors Holds January 2016 Board Meeting
PR Newswire - Fri Jan 22, 1:30PM CST
The Board of Trustees of Babson Capital Corporate Investors (the "Trust" met on January 22, 2016. The Trust's Trustees determined that the Trust's December 31, 2015 net asset value ("NAV" is $275,915,289 or $14.03 per share based on 19,664,704 shares outstanding. The Trust's December 31, 2014 NAV was $280,130,264 or $14.34 per share based on 19,533,416 shares outstanding. The Trust reported a NAV of $288,625,613 or $14.70 per share as of September 30, 2015, based on 19,633,590 shares outstanding. Unlike the NAV reported for quarters ended March 31, June 30, and September 30, the NAV for the quarter ended December 31 reflects the declaration of the quarterly dividend of $0.30 per share which was paid on January 15, 2016. All figures for 2015 are unaudited.
MCI: 17.63 (-0.26)

Uptrend Call Working As MassMutual Corporate Investors Stock Rises 11.7% (MCI)
Comtex SmarTrend(R) - Tue Dec 29, 10:46AM CST
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 24 months, MassMutual Corporate Investors has returned 11.72% as of today's recent price of $17.45.
MCI: 17.63 (-0.26)

Shares of MCI Up 11.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 22, 10:13AM CST
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 23 months, MassMutual Corporate Investors has returned 11.78% as of today's recent price of $17.46.
MCI: 17.63 (-0.26)

Babson Capital Corporate Investors declares quarterly dividend
M2 - Wed Dec 16, 5:47AM CST
The Board of trustees of Babson Capital Corporate Investors has declared a quarterly dividend of USD0.30 cents per share. The dividend is payable on January 15, 2016 to shareholders of record on December 31, 2015. The trustees of the CI Subsidiary Trust, a wholly owned subsidiary of the trust, declared a USD3.0 million distribution that was payable to the trust on December 3, 2015, made from accumulated income and capital gains. Babson Capital Corporate Investors is a closed-end management investment company advised by Babson Capital Management LLC (NYSE: MCI).
MCI: 17.63 (-0.26)

Babson Capital Corporate Investors Declares Quarterly Dividend of $0.30 per Share
PR Newswire - Fri Dec 11, 12:31PM CST
The Board of Trustees of Babson Capital Corporate Investors (the "Trust" met today. The Trust's Trustees declared a quarterly dividend of 30 cents per share payable on January 15, 2016 to shareholders of record on December 31, 2015. The quarterly dividend is considered ordinary income for tax purposes and will be reported on IRS Form 1099-Div. Although a 30 cent-per-share dividend was declared in each of the three preceding quarters, no assurance can be given that the Trust will be able to maintain that dividend level in the future.
MCI: 17.63 (-0.26)

MassMutual Corporate Investors Has Returned 12.2% Since SmarTrend Recommendation (MCI)
Comtex SmarTrend(R) - Thu Nov 19, 5:31PM CST
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 22 months, MassMutual Corporate Investors has returned 12.16% as of today's recent price of $17.52.
MCI: 17.63 (-0.26)

MassMutual Corporate Investors Up 6.9% Since SmarTrend Uptrend Call (MCI)
Comtex SmarTrend(R) - Mon Nov 02, 10:14AM CST
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 22 months, MassMutual Corporate Investors has returned 6.91% as of today's recent price of $16.70.
MCI: 17.63 (-0.26)

Babson Capital announces USD0.30 per share dividend for quarter
M2 - Thu Oct 29, 5:37AM CDT
Babson Capital Corporate Investors (trust) (NYSE:MCI) revealed on Wednesday that its board of trustees approved a quarterly dividend of USD0.30 per share.
MCI: 17.63 (-0.26)

Babson Capital announces USD0.30 per share quarterly dividend
M2 - Mon Oct 26, 4:14AM CDT
The board of trustees of Babson Capital Corporate Investors (NYSE:MCI) authorised a quarterly dividend of ISD0.30 per share, unchanged from the prior quarter, the company declared on Friday.
MCI: 17.63 (-0.26)

MassMutual Corporate Investors Up 10.1% Since SmarTrend Uptrend Call (MCI)
Comtex SmarTrend(R) - Fri Oct 23, 5:39PM CDT
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 21 months, MassMutual Corporate Investors has returned 10.05% as of today's recent price of $17.19.
MCI: 17.63 (-0.26)

Shares of MCI Up 8.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 16, 12:00PM CDT
SmarTrend identified an Uptrend for MassMutual Corporate Investors (NYSE:MCI) on January 17th, 2014 at $15.62. In approximately 21 months, MassMutual Corporate Investors has returned 8.58% as of today's recent price of $16.96.
MCI: 17.63 (-0.26)

Babson Capital announces quarterly dividend of USD0.30 per share
M2 - Thu Jul 23, 4:46AM CDT
The Babson Capital Corporate Investors (NYSE:MCI) revealed on Wednesday that its board of trustees approved a quarterly dividend of USD0.30 per share.
MCI: 17.63 (-0.26)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Insights from the New First Presidency on Global Challenges

Updated Category News Views 218

A Historic Conversation with the First Presidency The recent interview featuring the new First Presidency of The Church of Jesus Christ of Latter-day Saints marks an exciting milestone. Conducted by the talented Jane Clayson Johnson, this unique dialogue sheds light on pressing issues within the Church and broader society. It was their first public discussion, making it a...

Continue Reading
Major Bets on Donald Trump's Election Surge Past $52 Million

Updated Category News Views 119

Significant Bets on Trump's Electoral Success A trader on Polymarket, operating under the alias Fredi9999, alongside four other accounts, has made headlines recently by placing enormous bets on Donald Trump’s electoral prospects. This activity has generated considerable chatter among traders in the market. Tracking Trump's Betting Activity Harry Crane, a statistics...

Continue Reading
FMC Corporation Faces Lawsuit Over Securities Violations

Updated Category News Views 190

FMC Corporation Faces Lawsuit Over Securities Violations Recently, the Gross Law Firm has alerted shareholders of FMC Corporation (NYSE: FMC) regarding significant legal developments. This lawsuit brings attention to serious allegations concerning the company's conduct during a specific class period. Shareholder Engagement and Participation Shareholders who purchased FMC...

Continue Reading
Insider Buying at Optima Health Signals Confidence in Future Growth

Updated Category News Views 132

Insightful Insider Share Purchase at Optima Health Optima Health plc (AIM: OPT), a leading provider of corporate health and wellbeing solutions in the UK, recently announced an important transaction involving one of its key insiders. Joanne Newey, who takes on the role of Group Business Development & Propositions Director and is also a Person Discharging Managerial...

Continue Reading
Outlook Therapeutics Prepares for Upcoming Investor Interaction

Updated Category News Views 78

Outlook Therapeutics Connects with Investors at Upcoming Virtual Event ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related...

Continue Reading